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Sodium octanoate and N-acetyl-L-tryptophan (N-AcTrp) are widely used as stabilizers during pasteur-
ization and storage of albumin products. However, as compared with N-AcTrp, N-acetyl-L-methionine
(N-AcMet) is superior in protecting albumin exposed to light during storage. Here, we examine, whether
N-AcMet also is better than N-AcTrp to protect albumin against oxidation. Recombinant human serum
albumin (rHSA) without and with N-AcMet or N-AcTrp was oxidized by using chloramine-T (CT) as a
model compound for mimicking oxidative stress. Oxidation of rHSA was examined by determining
carbonyl groups and advanced oxidation protein products. Structural changes were studied by native-
PAGE, circular dichroism, intrinsic ﬂuorescence and differential scanning calorimetry. The anti-oxidant
capacity of CT-treated rHSA was quantiﬁed by its ability to scavenge peroxynitrite and the hydroxyl
radical. The pharmacokinetics of indocyanine green-labeled albumin preparations was studied in male
mice. We found that the number of chemical modiﬁcations and the structural changes of rHSA were
signiﬁcantly smaller in the presence of N-AcMet than in the presence of N-AcTrp. The anti-oxidant
properties of CT-exposed rHSA were best protected by adding N-AcMet. Finally, N-AcMet is superior in
preserving the normal pharmacokinetics of rHSA. Thus, N-AcMet is superior to N-AcTrp in protecting
albumin preparations against oxidation. In addition, N-AcMet is probable also useful for protecting other
proteins. Therefore, N-AcMet should be useful as a new and effective stabilizer and antioxidant for al-
bumin isolated from blood, rHSA, albumin-fusion proteins and for preparations of rHSA-therapeutic
complexes.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human serum albumin (HSA) is a major component of the
circulating blood, accounting for approximately 60% of plasma
protein, and it is the main contributor to the vascular osmotic
pressure [1]. Therefore, albumin preparations have long been usedB.V. This is an open access article u
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.as a plasma substitute in clinical practice, such as for the emer-
gency treatment of shock, the restoration of blood volume, the
acute management of burns, and in other clinical situations asso-
ciated with hypoproteinemia [2]. In addition to its osmotic effect,
HSA also has various other functions [1]. For instance, HSA shows a
high afﬁnity for many endogenous as well as exogenous sub-
stances, such as drugs and toxins, and thereby affects their phar-
macokinetics and consequently their physiological activity and
drug efﬁcacy [3,4]. HSA also plays an important role as a major
anti-oxidant in plasma and extracellular compartments, mainly
because the cysteine in position 34 (Cys34) of HSA accounts for
approximately 70% of all free sulfhydryl (SH) groups in plasma [5].
These ﬁndings suggest that HSA has an important role in the
maintenance of biological homeostasis.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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HSA is expected to have several beneﬁcial effects. At present, the
only source of HSA for clinical use is human blood. However, blood
can contain viruses or other pathogens, which can cause disease in
the recipients. That is why HSA preparations are pasteurized be-
fore clinical use. However, due to its long circulating half-life of ca.
19 days, HSA is subject to a variety of post-translational mod-
iﬁcations in vivo as a result of various stress conditions, such as
oxidation and glycation [1,6]. Thus, albumin products prepared
from pooled plasma sources can be post-translationally modiﬁed
[7]. Such modiﬁcations often compromise albumin's functions,
other than its osmotic pressure maintaining function. In fact, some
research groups have reported that HSA is functionally impaired in
a disease state, and that this alteration is associated with disease
progression [8,9]. Therefore, having albumin preparations in which
the HSA functions during storage and upon administration are
preserved with minimal additional modiﬁcations would be highly
desirable.
Several complexes of recombinant HSA (rHSA) and a ther-
apeutic are now available for clinical use. In addition, other such
complexes as well as fusion proteins and rHSA itself are in dif-
ferent types of clinical trials. Also in these cases it is important to
be able to store the products without risking modiﬁcations such as
oxidation.
For stabilizing HSA during pasteurization it is common to add
the ligands octanoate (Oct) and N-Acetyl-L-tryptophan (N-AcTrp).
We have previously studied the effects of these additives during
pasteurization and found that Oct has a good stabilizing effect
against heat, whereas the presence of N-AcTrp diminishes oxida-
tion of HSA [10]. More recently, we have studied whether
N-Acetyl-L-methionine (N-AcMet) could be used as a photo-sta-
bilizer during prolonged storage instead of N-AcTrp. The problem
associated with the use of N-AcTrp for that purpose is that it can
be easily oxidized by light exposure, and thereby photo-degraded.
The products formed can oxidize HSA and have been reported to
be neurotoxic [11]. The reason for using N-AcMet in this respect
was that methionine itself is susceptible to oxidation by almost all
forms of reactive oxygen species (ROS) and thereby could protect
HSA. We found that N-AcMet is an effective protector of albumin
against photo-oxidation [12]. However, until now we had not ex-
amined the usefulness of N-AcMet for protecting HSA or rHSA
against other types of oxidation relevant for storage and
administration.
In the present study, therefore, we have examined the protec-
tive effect of N-AcMet on the oxidation of rHSA and compared it
with that of N-AcTrp. Chloramine-T (CT) was used as a model
compound for mimicking oxidative stress. The extent of rHSA
modiﬁcations and the effects on protein structure were studied by
several physico-chemical methods. Likewise were the anti-oxidant
properties of CT-exposed rHSA, without and with additive, quan-
tiﬁed. Finally, the pharmacokinetics of the different albumin pre-
parations was investigated by using mice. The results revealed that
N-AcMet has a superior protective effect on rHSA against oxida-
tion. Therefore, N-AcMet should be very useful as a stabilizer
against oxidation during storage and upon administration.2. Materials and methods
2.1. Materials
Male ddY mice were purchased from Kyudo Co., Ltd, Saga, Ja-
pan. rHSA was a gift from Nipro Corporation (Shiga, Japan) and
defatted using charcoal treatment as described by Chen [13]. After
dialysis against distilled water, the protein was freeze-dried and
stored at 20 °C until use. N-AcTrp and CT were purchased fromWako (Tokyo, Japan), and N-AcMet was bought from MP Biome-
dicals (Solon, OH, USA). Peroxynitrite solution was obtained from
Chemical Dojin Co. Ltd. (Kumamoto, Japan). All solutions were
prepared in deionized and distilled water and kept in a sterile
room.
2.2. Oxidation of rHSA by CT without and with additives
For preparing oxidized rHSA by CT-treatment in the absence
and in the presence of N-AcMet (75 μM) or N-AcTrp (75 μM), rHSA
(15 μM) was incubated for 1 h in phosphate buffer (pH 7.4) at 37 °C
in an oxygen-saturated solution containing CT alone (5 mM) (non-
additive CT-HSA) or with N-AcMet (CT-HSA with N-AcMet) or
N-AcTrp (CT-HSAwith N-AcTrp). This molar ratio between additive
and protein was chosen, because HSA used in the clinic, pharma-
ceutical-grade albumin, is pasteurized and delivered with Oct and
N-AcTrp in molar ratios to albumin of approximately 5–1. After
incubation, the oxidative processes were stopped by cooling and
by dialysing the solutions extensively against water. A control was
made by incubating albumin dissolved in buffer alone, and in all
cases the proteins were freeze-dried after dialysis and stored at
20 °C until use.
2.3. The extent of rHSA oxidation without and with additives
2.3.1. Carbonyl contents of oxidized rHSA
The degree of rHSA oxidation was evaluated by running native-
PAGE on Novex Tris-Glycine gels [14], by measuring carbonyl
contents and by using Western blotting. Carbonyl groups were
quantitated as described by Climent et al. [15]. Brieﬂy, the carbonyl
groups were derivatized with ﬂuoresceinamine, and their number
was determined from the absorbance of the complexes at 490 nm
(Jasco Ubest-35 UV/VIS spectrophotometer). The level of rHSA
oxidation was also quantitated by Western blot analysis as de-
scribed by Anraku et al. [16]. The protein was derivatized with
dinitrophenylhydrazine (DNP) using an OxyBlot Kit (Serologicals
Corporation, Norcross, GA, USA). Afterwards, samples were elec-
trophoresed on duplicate SDS-PAGE gels. Following electrotransfer
to a polyvinylidene diﬂuoride membrane, one blot was stained for
DNP using the OxyBlot Kit reagents. The second blot was stained
with Coomassie brilliant blue G for protein. All rHSAs had identical
reactivity with polyclonal antiserum using the ELISA method (data
not shown). Bands were visualized with chemiluminescent che-
micals and captured on ﬁlm at 10 min DNP and protein blots were
scanned using the same size section of the blot for each scan. The
results obtained are reported as DNP area/protein area and are
given in densitometry units.
2.3.2. Advanced oxidation protein products (AOPP) contents of oxi-
dized rHSA
Protein samples were treated with potassium iodide as de-
scribed by Witko-Sarsat et al. [17], and AOPP contents were as-
sessed by measurement of the absorbance at 340 nm. Speciﬁcally,
CT standard solutions 0–100 μmol/L) were placed in the wells of a
96-well microtiter plate, followed by 20 μL of acetic acid. 10 μL of
1.16 M potassium iodide (KI) was then added, followed by 20 μL of
acetic acid. The absorbance of the reaction mixture was im-
mediately read at 340 nm in a microplate reader against a blank
containing 200 μL of phosphate buffer, 10 μL of KI and 20 μL of
acetic acid. The CT absorbance at 340 nm was linear within the
range of 0–100 μmol/L. AOPP concentrations were expressed in
μmol/L of CT equivalents.
2.3.3. Peroxynitrite scavenging activity of oxidized rHSA
The amount of peroxynitrite was evaluated by the extent of
dihydrorhodamine 123 oxidation. 50 μL of gelatin (1.2 mg/mL),
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oxidized rHSA were added to a 96-well plate, and then incubated
for 5 min Before incubation, 50 μL aliquots of the peroxynitrite
solution (0.28 mM) were added to the above prepared solutions.
After the 5 min incubation, the ﬂuorescence of the rhodamine 123
formed was measured at 535 nm after having been excited at
500 nm [18,19]. Peroxynitrite scavenging activity was estimated
from the decrease in ﬂuoresence of the rhodamine 123 according
to the following equation:
( )
= − (
× ) ( )
Radical scavenging activity %
100 fluorescence with albu min samples/
fluorescence without albu min samples 100 . 1
2.3.4. Hydroxyl radical (OH) scavenging activity of oxidized rHSA
Hydroxyl radicals (OH) were formed by iron-catalyzed Haber-
Weiss reaction (Fenton driven Haber-Weiss reaction), and they
reacted rapidly with the nitrone spin trap DMPO [20]. The re-
sultant DMPO-OH product was detectable with an ESR spectro-
meter. In practice, 0.2 mL of the different albumin forms (50 μM)
were mixed with DMPO (0.3 M, 0.2 mL), Fe2SO4 (0.5 mM, 0.2 mL)
and H2O2 (4 mM, 0.2 mL) in a sodium phosphate buffer solution
(pH 7.4), and then transferred to 100 μL quartz capillary tubes.
After 2 min, the ESR spectrum was recorded using an X-band ESR
spectrometer (JES-FA100, JEOL Ltd., Tokyo, Japan) under the fol-
lowing conditions: microwave frequency 9.417 GHz, microwave
power 8 mW, ﬁeld modulation 0.1 mT at 100 kHz, and sweep time
2 min After recording the EPR spectra, the signal intensities of the
DMPO-OH adducts were normalized against that of a manganese
oxide (Mn2þ) signal, where Mn2þ is an internal control. The
scavenging activity was calculated from the relative intensity peak
height of the DMPO-OH EPR signal [21], compared to the in-
tensities observed in the absence of oxidized HSAs, using Eq. (2).
( )
= − (
× ) ( )
ROS scavenging activity %
100 relative intensity with albu min samples/relative
intensity without albu min samples 100 . 2
2.4. Structural stability of rHSA oxidized without and with additives
2.4.1. Far-UV circular dichroism (CD) spectra of oxidized HSA
Far-UV CD spectra (200–250 nm) were recorded with a Jasco
J-720 type spectropolarimeter (Tokyo, Japan) using 1 mm path-
length cells. The ﬁnal concentration of native and oxidized rHSA
was 10 mM, and that of each additive was 50 mM; the medium was
67 mM sodium phosphate buffer, pH 7.4 and 25 °C.
2.4.2. Differential scanning calorimetry (DSC)
Differential scanning calorimetry was carried out with the
different albumin forms and by using a Nano-DSC (TA Instruments,
Newcastle, USA) using heating rates of 1 K/min. The ﬁnal protein
concentration was 20 mM and that of each additive was 100 mM in
67 mM sodium phosphate buffer, pH 7.4. The results showed, as
also observed by Picó [22], that heating to or above 85 °C caused
irreversible denaturation. The data obtained from DSC were ap-
plied to nonlinear ﬁtting algorithms to calculate the thermo-
dynamic parameters, namely thermal denaturation temperature
(Tm), calorimetric enthalpy (ΔHcal) and van’t Hoff enthalpy (ΔHv),
from the temperature dependence of excess molar heat capacity,
Cp, by employing Using OriginTM scientiﬁc plotting software.
2.4.3. Effect on aromatic amino acid residues
Steady-state ﬂuorescence measurements were made using a
Jasco FP-770 ﬂuorometer with 1 cm quartz cells and thermostateddevices. All studies were performed with a ﬁnal protein con-
centration of 2 mM at 25 °C using 5 nm excitation and emission
band widths. A ﬂuorescence excitation wavelength of 295 nm was
employed for mainly exciting the lone tryptophan residue in po-
sition 214. Absorbance spectra (200–400 nm) of the albumins
(20 mM) were recorded at 25 °C with 1 cm quartz cells by using the
Jasco UV/VIS spectrophotometer.2.5. In vivo ﬂuorescence imaging of rHSA oxidized without and with
additives
All animal experiments were approved by the Animal Care and
Use Committee of Sojo University. Care and handling of the ani-
mals were performed in accordance with the guidelines, princi-
ples, and procedures for the care and use of laboratory animals of
Sojo University. All male, 7–9 week-old ddY mice were maintained
under conventional housing conditions. The animals were accli-
mated for 1 week before the experiments. Prior to the experi-
ments, the mice fasted overnight but had free access to water. ICG
(Indocyanine green)-labeled rHSA was prepared using ICG Label-
ing Kit-NH2 (Dojindo Molecular Technologies, Inc). The mice were
injected with 1 mg of native or oxidized rHSA labeled with ICG per
kg i.v. At different times after injection, blood was collected from
the vena cava under ether anesthesia, and plasma was obtained by
centrifugation. The ﬂuorescence of the plasma samples was mea-
sured using the Jasco FP-770 ﬂuorometer (excitation at 774 nm
and emission at 805 nm) [23].2.6. Statistics
Pharmacokinetic analyses of the samples were conducted using
a non-compartment model. Pharmacokinetic parameters were
calculated using the moment analysis program available with
Microsoft Excel (Microsoft Corp.). Data are shown as the mean
7S.D. for the indicated number of animals. Other results are also
reported as mean 7S.D. Statistical signiﬁcance was evaluated
using ANOVA followed by the Newman-Keuls method for com-
parisons of more than two means. A value of Po0.05 was regarded
as statistically signiﬁcant.
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Fig. 2. (A) Carbonyl content of non-treated rHSA (control) and oxidized rHSAs. The concentration of rHSA was 0.2 mM and that of each additive was 1 mM. Each column
represents the mean 7 S.D. (n ¼3). nnPo0.01, compared with control. ##Po0.01, compared with CT-rHSA additive (-). ††Po0.01, compared with CT-rHSA þ N-AcTrp.
(B) Native-PAGE electrophoresis. The concentration of rHSA was 0.1 mM and that of each additive was 0.5 mM. (C) Western blots and staining with Oxyblot Kit reagents.
(D) Level of rHSA oxidation as determined by densitometry ratios between DNP area and corresponding protein area. Each column represents the mean 7 S.D. (n¼4). ##
Po0.01, compared with CT-rHSA additive (-). †† Po0.01, compared with CT-rHSA þ N-AcTrp.
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3.1. The level of rHSA oxidation without and with additives
3.1.1. AOPP contents
As seen in Fig. 1, treatment of rHSA with CT increases the AOPP
content of the protein very much, i.e., from 5.371.3 mM to
62.572.3 mM (po0.01). The value obtained for the CT-treated
albumin (non-additive CT-rHSA) corresponds to those of the pro-
teins in uremic plasma [24]. This ﬁnding suggests that the state of
non-additive CT-rHSA reﬂects the state of AOPP in uremia [25].
Oxidation in the presence of N-AcMet or N-AcTrp results in a de-
creased amount of AOPP. In particular, the protective effect of
N-AcMet is pronounced, because the AOPP formed in its presence
is diminished to 45% of that formed without additive (po0.01).
The content is also signiﬁcantly lower than that formed in the
presence of N-AcTrp, which results in the formation of 57% of that
formed without additive (po0.01).3.1.2. Carbonyl contents
The extent of oxidation of rHSA after CT-induced oxidative
stress was also evaluated by measuring the content of carbonyl
groups by spectrophotometry after their derivatization with
ﬂuoresceinamine. As seen in Fig. 2A, N-AcTrp but especially
N-AcMet has protective effects against oxidation, i.e., the carbonyl
contents were diminished by 16% and 29%, respectively, as com-
pared to the content measured without additive.3.1.3. Native-PAGE
Fig. 2(B) shows the effect of oxidation on the migration and
broadening of rHSA using native-PAGE. As seen, treatment of rHSA
alone or in the presence of N-AcTrp effected the albumin migra-
tion and caused a clear broadening of the major protein bands.
These effects were less pronounced, if the oxidation took place in
the presence of N-AcMet.
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Fig. 5. Thermogram of non-treated rHSA (control) and oxidized rHSAs obtained by
DSC. (1) control, (2) CT-rHSA additive (-), (3) CT-rHSA þ N-AcMet, (4) CT-rHSA þ
N-AcTrp dissolved in sodium phosphate buffer, pH 7.4. The protein concentration
was 20 mM.
Table 1
Thermodynamic data obtained from DSC of different rHSA samples after CT-in-
duced oxidation.a
Protein samples Tm (°C) ΔHcal (kcal/
mol)
ΔHv (kcal/mol) ΔHv/ΔHcal
Control 60.870.09 12673.0 83.874.1 0.6670.20
CT-rHSA ad-
ditives (-)
61.770.07 48.272.5nn 56.973.4nn 1.1870.10
CT-rHSA þ
N-AcMet
61.270.05 91.974.9nn 64.172.9nn 0.7070.18##, †
CT-rHSA þ
N-AcTrp
62.370.10 54.373.9nn 57.471.9nn 1.0672.9
a The concentration of rHSA was 20 mM and that of each additive was 100 mM.
The results are means 7 S. D. (n¼3).
nn Po0.01, compared with control.
## Po0.01, compared with CT-rHSA additive (-).
† Po0.05, compared with CT-rHSA þ N-AcTrp.
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The carbonyl contents of oxidized rHSAs were also determined
by Western blot analysis using an anti-DNP antibody (Fig. 2C). The
content of carbonyl groups in untreated and in oxidized rHSA was
calculated as the densitometry ratio between the DNP area and the
corresponding protein area (see Section 2.3.1.). These carbonyl/
protein ratios are regarded as relative oxidized rHSA ratios and are
given in Fig. 2D. As seen, only CT-HSA with N-AcMet decreased
slightly, but signiﬁcantly, the carbonyl/protein ratio, whereas
N-AcTrp had no signiﬁcant effect on the ratio. Thus, taking all of
the results in Fig. 2 into account, N-AcMet seems to be the most
effective additive in protecting rHSA against oxidation.
3.1.5. Peroxynitrite scavenging activity
In this experimental set-up, peroxynitrite can have two effects.
It can either oxidize albumin, or it can oxidize dihydrorhodamine
123 to rhodamine 123, the ﬂuorescence of which is measured.
Therefore, the better antioxidant, the higher peroxynitrite
scavenging activity and the lower ﬂuorescence. As seen in Fig. 3,
the scavenging activity of CT-rHSA with N-AcMet is most pro-
nounced of the three oxidized albumin preparations. This effect is
observed, because the antioxidant properties of rHSA are best
protected by N-AcMet.
3.1.6. OH scavenging activity
ROS such as OH lead to cell death and trigger various diseases
related to oxidative stress. Therefore, the scavenging effect of the
additives on OH species was evaluated by means of an ESR spin-
trapping method, namely by monitoring the intensity of ESR sig-
nals of DMPO-OH adducts produced by the reaction of DMPO with
OH. The ESR intensities of the DMPO-OH adduct were reduced by
the addition of additives, indicating that OH species were sca-
venged. The relative intensity of the DMPO-OH adducts compared
to an external reference of Mn2þ was plotted to calculate the
scavenging ability (%) of additives. As seen in Fig. 4, the OH
scavenging activity of CT-rHSA with N-AcMet was found to be
superior to that of CT-rHSA with N-AcTrp and much higher than
that observed for CT-rHSA without additive. As in the case of the
peroxynitrite scavenging activity (see Section 3.1.5.) these ﬁndings
are in accordance with the proposal that N-AcMet is a better
protector against oxidation than N-AcTrp.
3.2. Structural characteristics of rHSA oxidized without and withadditives
3.2.1. DSC-studies
The thermal denaturation of rHSA oxidized in the absence and
presence of an additive was examined by means of DSC mea-
surements (Fig. 5). As quantitated in Table 1, the denaturation
temperature (Tm) was not signiﬁcantly affected by oxidation. The
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more easily denatured, which again implies that the protein
structures are more open (i. e. more hydrophobic regions are ex-
posed to the solvent) at 25 °C. This suggestion was tested by using
the ﬂuorescence probe bis-ANS, which binds to hydrophobic areas.
The results obtained with bis-ANS also strongly indicate the for-
mation of additional accessible hydrophobic areas in rHSA oxi-
dized in the presence of N-AcTrp. By contrast, only small changes
take place in the case of rHSA oxidized in the presence of N-AcMet
(data not shown). The denaturation enthalpies (ΔHv) were af-
fected as follows: Control-rHSA 4 non-additive CT-rHSA  CT-
rHSA with N-AcMet  CT-rHSA with N-AcTrp. The ΔHv/ΔHcal-
values, and the corresponding broadening of the peaks in Fig. 5,
indicate that, although the thermal denaturation of the protein
forms takes place at the same temperature, the denaturation of
rHSA þ N-AcMet probably involves intermediary steps, because
the ΔHv/ΔHcal-value is below 1. By contrast, denaturation of
rHSA þ N-AcTrp could involve some multimerisation of the pro-
tein, because the ΔHv/ΔHcal-value is slightly above 1. Thus, the
DSC-studies suggest that the structural changes of rHSA are sig-
niﬁcantly smaller in the presence of N-AcMet than in the presence
of N-AcTrp.
3.2.2. CD spectra
As can be seen in Fig. 6, CT-induced oxidation decreased in all
examples the α-helical content of rHSA. The decrease was smallest
for CT-rHSA with N-AcMet, namely 6.8%. In the other cases, the
decreases for CT-rHSA with N-AcTrp and non-additive CT-rHSA,
were 15.5% and 16.2%, respectively. These ﬁndings also suggest a
superior role for N-AcMet in protecting rHSA during CT induced
oxidation.
3.2.3. Effect on aromatic amino acid residues
The effect of oxidation on the single tryptophan residue in
position 214 in albumin was monitored by ﬂuorescence mea-
surements (Fig. 7). As seen, CT-rHSA with N-AcMet resulted in the
smallest decrement in the ﬂuorescence, i.e., 48.2% at λmax. In
contrast, CT-rHSA with N-AcTrp and, especially, non-additive CT-
rHSA had much lower ﬂuorescence intensities, i.e., the decreases
were 80.2% and 83.8%, respectively. Likewise, the shift of λmax
towards shorter wavelengths seems to be most pronounced in the
latter two cases. The light absorbance spectra from 200 nm to
400 nm were affected in principally the same manner as found forthe ﬂuorescence spectra (not shown). The changes in the two
types of spectra suggest that minor conformational changes have
taken place in the vicinity of the tryptophan residue, and that the
changes are most pronounced for CT-rHSA oxidized without or
with N-AcTrp. In this connection it is of interest to note that na-
tive-PAGE of rHSA þ N-AcTrp and of rHSA alone showed a more
evident effect on albumin migration and on the width of the major
protein bands (Fig. 2(B)). These indications of aggregate formation
are in accordance with transfer of Trp214 to a more hydrophobic
environment (Fig. 7).
3.3. Plasma half-lives of rHSA oxidized without and with additives
In an attempt to evaluate whether CT-induced oxidations
without and with additives had any effect on the biological fate of
rHSA, we determined plasma half-lives of the rHSAs in mice
(Fig. 8). CT-rHSA with N-AcTrp (t1/2¼4.98 h) and non-additive CT-
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that of CT-rHSA with N-AcMet (t1/2¼5.87 h) and control-rHSA (t1/2
¼9.65 h). Fluorescence measurements carried out with isolated
organs showed that liver uptakes of CT-rHSA with N-AcTrp and
non-additive CT-rHSA were much more pronounced than that of
control rHSA and CT-rHSA with N-AcMet (not shown). This ﬁnding
most probably explains the shorter half-lives of the two former
preparations.4. Discussion
The annual production of puriﬁed HSA for clinical purposes
now exceeds 300 t [1]. In addition, rHSA with bound therapeutics
are already used in the clinic, and rHSA, without or with other
therapeutics, and albumin fusion proteins are soon available for
clinical use. Therefore, it is surprising that only sparse information
can be found about the mechanism of protection of the standard
additives Oct and N-AcTrp during any pasteurization and during
storage and about their potential adverse effects caused by their
presence in the albumin products. Previously, we have studied the
effects of these additives during pasteurization and found that Oct
has a good stabilizing effect against heat, whereas the presence of
N-AcTrp diminishes oxidation of HSA [10]. It is commonly ac-
cepted that albumin products with these additives can be stored at
room temperature for as long as two years [1]. We have recently
found that N-AcMet is a safe and risk-free stabilizer of albumin
during photo-irradiation for long storage [12]. Actually, N-AcMet is
superior to N-AcTrp in this respect, because exposure to light
photo-degrades the latter to potentially toxic compounds which
promotes photo-oxidative damage of albumin. However, it is not
known whether oxidation can affect the quality of albumin pro-
ducts during long storage or upon administration, and how it is
possible to diminish any such changes. In the present study we
investigated the protective effects of N-AcMet, compared with
those of N-AcTrp, and used CT as a model compound for mi-
micking oxidative stress.
Dependent on the molar ratio between CT and albumin, CT is
able to oxidize with increasing efﬁciency Cys34, methionine re-
sidues, Trp214, arginine, lysine and proline residues in the protein
[26–28]. In accordance with this, we found that CT-treatment of
rHSA resulted in the formation of a pronounced content of AOPP
(Fig. 1) and carbonyl groups (Fig. 2). The results also clearly
showed that N-AcMet is a better protector against the CT-induced
oxidation than N-AcTrp. Furthermore, the antioxidant properties
of rHSA are best preserved, when the treatment with CT takes
place in the presence of N-AcMet. Thus, this type of preparation is
superior in scavenging peroxynitrite (Fig. 3) and the hydroxyl ra-
dical (OH) (Fig. 4). Taking all of these results into consideration,
N-AcMet is more efﬁcient than N-AcTrp in protecting rHSA against
oxidation. In this respect it is of interest to note that we have
previously found that N-acetyl-cysteinate has no protective effect
against oxidation, because N-acetyl-cysteinate interacts covalently
with the thiol group of Cys34 [10].
What residues in rHSA are mostly affected by the CT-induced
oxidation? Bourdon et al. [27] have reported that among the 585
amino acid residues in HSA, Cys34 and the methionine residues
account for 40–80% of the total antioxidant activity of the protein.
We have previously quantitatively evaluated the role of these re-
sidues for the antioxidative activity of rHSA using recombinant
mutants, in which Cys34 and/or the six methionine residues had
been mutated to alanine using site-directed mutagenesis [21,28].
The results showed that the level of contribution of Cys34 and the
methionine residues to the antioxidative activity of rHSA was 61%
and 29% against O2 , 68% and 61% against H2O2, 38% and 6%
against OH, 36% and 13% against HOCl and 51% and 1% againstNO, respectively. This information suggests that especially Cys34
but also the methionine residues are mostly involved in the pre-
sent CT-induced oxidation, because CT oxidizes via the formation
of OH and chloro radicals [28].
Differential scanning calorimetry is a powerful method that
provides a complete thermodynamic characterization of the sta-
bility of a protein as a function of temperature [29,30]. Therefore,
to validate the beneﬁt of N-AcMet as a structural stabilizer, we also
studied the stabilizing effect of N-AcMet against CT-induced oxi-
dation by DSC. We observed that the endotherms were single
peaks, indicating that thermal denaturation can be explained by a
single component model (Fig. 5) [22, 29–31]. Therefore, single
values for Tm, ΔHcal and ΔHv could be calculated (Table 1).
ΔHcal, which is generally thought to reﬂect the hydration of hy-
drophobic regions buried in the native protein structure during
the unfolding process, is higher for rHSA oxidized in the presence
of N-AcMet than in the presence of N-AcTrp. The ratio of ΔHv/
ΔHcal is an index of the transition process to the denaturation
states of proteins during thermal denaturation [32]. The value of
this ratio for control-HSA was almost identical to that for CT-HSA
with N-AcMet, whereas those for CT-HSA with N-AcTrp and non-
additive CT-HSA increased. Thus, N-AcMet gave a greater protec-
tion against oxidative stress than N-AcTrp.
In an attempt to differentiate the conformational changes of
the three oxidized rHSA preparations detected by DSC, we studied
their CD, ﬂuorescence and light absorbance spectra. The CD
spectra revealed only a minor decrease in the α-helical content of
rHSA, when oxidation took place in the presence of N-AcMet. By
contrast, almost no protective effect was observed by N-AcTrp
(Fig. 6). The ﬂuorescence and light absorbance measurements also
showed conformational changes in all three cases, but they were
less pronounced if the CT-treatment took place in the presence of
N-AcMet (Fig. 7 and not shown). The modiﬁed spectra reﬂect
conformational changes involving Trp214, caused by oxidation of
the residue itself or indirectly by oxidation of Cys34 and/or one or
more methionine residues. In conclusion, N-AcMet is more useful
than N-AcTrp as a structural stabilizer.
N-AcMet binds to one site on native rHSA with a low afﬁnity,
i.e., Kass¼5.5104 M1 [12]. Thus, the protective effect of N-Ac-
Met is not due to a strong binding, why it should also be useful as a
stabilizer for other solubilized proteins.
The clearance of albumin depends on various factors including
its degradation by a variety of organs, transcapillary escape, ﬁl-
tration and reabsorption, lymphatic drainage just to name a few.
These pathways in turn are also inﬂuenced by the physicochemical
state of the protein such as its charge and conformation. In skin,
the clearances for the most neutral modiﬁed albumins and ca-
tionic albumins were found to be 20% and 80% greater than that
for native albumin, respectively. In skeletal muscle, the clearances
for the most neutral modiﬁed albumins and cationic albumins
were found to be 50% and 1.5 times greater than that for native
albumin, respectively. This clearly shows that charge affects the
transvascular transport of albumin [33,34]. In addition, environ-
mental factors such as the presence of nitric oxide have been re-
ported to inﬂuence the extravasation of albumin [35]. We found
that the rate of protein clearance from the blood also depends on
the degree of oxidation (Fig. 8). One reason for the shorter half-life
and increased liver uptake of oxidized HSA could be the induced
conformational changes. In this connection, it is noteworthy that
Iwao et al. [36] reported a correlation between α-helix contents
and the in vivo degradation rates of modiﬁed albumins. In the
present work, the CT-induced oxidation also results in a slight
decrease in α-helix content of the protein (CT-rHSA additive (-)
(52.272.9%)o CT-rHSA with N-AcTrp (52.872.35%)o CT-rHSA
with N-AcMet (61.573.21%)o control rHSA (68.371.18%)). Fur-
thermore, we also found a good linear relationship between half-
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not shown). In other studies with genetic variants of HSA, Iwao
et al. [37,38] found that the diminished half-lives of their HSA
preparations were accompanied by increased liver uptake clear-
ances. Principally the same observation was made in the case of
the present preparations of oxidized rHSA (not shown).
Uptake of albumin by the liver is mainly due to the presence of
cell membrane receptors which recognize the protein and then
internalize it by endocytosis. Several possibilities seem to exist.
Among the receptors is one which is engaged in the rapid uptake
of oxidized albumin. Other possibilities are scavenger receptors
such as gp18 and gp30, but it is at present only speculative whe-
ther or not the present albumin forms can interact with them.
Finally, liver uptake by adsorptive endocytosis could be inﬂuenced
by the amino acid changes, because this type of uptake is depen-
dent on the net charge of the protein, which most probably is
modiﬁed in the present albumin forms. However, the detailed
mechanism for the liver uptake of oxidized albumin remains to be
clariﬁed.
In recent years, technology for the mass production of re-
combinant rHSA has been established [39]. Therefore, in the near
future, highly stable and inexpensive rHSA stabilized by N-AcMet
could be available for clinical and other applications.5. Conclusion
Apparently, the roles of N-AcMet and N-AcTrp for the post-
translational oxidation of albumin have not been studied before.
We found that N-AcMet is superior to N-AcTrp with respect to
scavenge ROS and to protect the protein against oxidation. Fur-
thermore, N-AcMet has a good stabilizing effect on protein struc-
ture and on its anti-oxidant properties. Finally, the reduced oxi-
dized rHSA burden helps maintain normal pharmacokinetics.
Thus, N-AcMet should be useful as a new stabilizer and anti-
oxidant for preparations of albumin and other solubilized proteins.
We expect N-AcMet will be approved as a new stabilizer in the
near future.Acknowledgements
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